Waldencast Offloads Obagi Medical for $460 Million to Focus on Milk Makeup

Why It Matters

By shedding Obagi, Waldencast can allocate capital to accelerate Milk Makeup’s global expansion while reducing leverage, improving shareholder returns. The sale also underscores rising private‑equity appetite for high‑growth dermatology brands.

Key Takeaways

• Waldencast sells Obagi Medical to Bridgepoint for $460 million.
• Sale allows Waldencast to concentrate exclusively on Milk Makeup.
• Founders Brousset and Sebti exit to lead Obagi with Bridgepoint.
• Proceeds will repay senior term‑loan and fund Milk Makeup expansion.
• Novaestiq and Obagi Japan rights also transferred to Bridgepoint.

Pulse Analysis

Waldencast’s origins as a 2021 SPAC gave it a rapid acquisition runway, first snapping up Obagi Medical and Milk Makeup in 2022 to create a $1.2 billion beauty platform. After a strategic review, the company is now pruning its portfolio, a move that mirrors a broader post‑SPAC trend where investors prioritize operational focus over diversified holdings. The $460 million Obagi sale not only provides a clean exit for founders Michel Brousset and Hind Sebti but also hands the dermatology brand to Bridgepoint, a private‑equity firm eager to build a mega‑brand in the skin‑care space.

For Milk Makeup, the cash infusion translates into a stronger balance sheet and the ability to retire its senior term‑loan, freeing up liquidity for product innovation, international rollout, and marketing spend. With the beauty market still fragmented, a focused capital strategy positions Milk Makeup to capture higher‑margin segments and leverage its celebrity‑backed DNA. Analysts expect the brand’s next growth phase to hinge on expanding distribution in Europe and Asia, where consumer demand for inclusive, high‑performance cosmetics remains robust.

The transaction also highlights private‑equity’s growing appetite for high‑growth, physician‑endorsed skincare brands. Bridgepoint’s acquisition of Obagi, along with Novaestiq and the Obagi Japan trademark, creates a consolidated platform that can benefit from economies of scale, cross‑selling, and accelerated R&D. As dermatology merges with beauty, firms that can navigate regulatory pathways while delivering consumer‑facing products are poised for outsized returns, making this deal a bellwether for future consolidation in the wellness‑beauty nexus.